


Product Details

Product name:	Anti-human CTLA-4 / CD152 (ipilimumab Biosimilar)	SKU:	BIO0018SM
Target Name:	CTLA-4 / CD152	Size:	1 mg/5 mg/20 mg
Target Uniprot:	P16410	Concentration:	Lyophilized
Clone#:	ipilimumab	Isotype:	Human IgG1
Reactivity:	Human, Cynomolgus	Calculated M.W.:	145.38 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	0.1M Pro, 20mM Arg, pH5.0	Conjugation:	None
Storage:	For long term storage, the produce should be stored at -20° C or lower.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH2O	Purification:	Protein A


Data

Purity:SDS-PAGE




Anti-CTLA-4 / CD152 (ipilimumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC




The purity of Anti-CTLA-4 / CD152(ipilimumab) is 99.37%, determined by SEC-HPLC.

Bioactivity:FACS



Human CTLA-4 & Human PD-1 CHO-K cells were stained with Anti-CTLA-4 / CD152 (ipilimumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2270 ug/mL.

Research in vivo



Ipilimumab inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects, with a tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.